In-vivo detection of the erythropoietin receptor in tumours using positron emission tomography

[1]  A. Kjaer,et al.  Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors. , 2014, Nuclear medicine and biology.

[2]  Lin Zhao,et al.  Protection effect of sanguinarine on whole-body exposure of X radiation in BALB/c mice , 2014 .

[3]  S. Sułkowski,et al.  The relationships between hypoxia-dependent markers: HIF-1alpha, EPO and EPOR in colorectal cancer. , 2014, Folia histochemica et cytobiologica.

[4]  S. Elliott,et al.  Progress in detecting cell-surface protein receptors: the erythropoietin receptor example , 2013, Annals of Hematology.

[5]  K. Pienta,et al.  Erythropoietin supports the survival of prostate cancer, but not growth and bone metastasis , 2013, Journal of cellular biochemistry.

[6]  M. Todaro,et al.  Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy. , 2013, Cancer research.

[7]  M. Yanagita,et al.  Renal anemia: from incurable to curable. , 2013, American journal of physiology. Renal physiology.

[8]  M. Ferracin,et al.  miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression , 2013, Molecular Cancer.

[9]  W. Berger,et al.  Erythropoietin Receptor Expression Is a Potential Prognostic Factor in Human Lung Adenocarcinoma , 2013, PloS one.

[10]  S. Goodison,et al.  Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions , 2013, Journal of Hematology & Oncology.

[11]  R. Lecomte,et al.  (68)Ga/DOTA- and (64)Cu/NOTA-phthalocyanine conjugates as fluorescent/PET bimodal imaging probes. , 2013, Bioconjugate chemistry.

[12]  Twan Lammers,et al.  Comparison and systematic optimization of synthetic protocols for DOTA–hydrazide generation , 2013 .

[13]  Fabian Kiessling,et al.  Noninvasive optical imaging of nanomedicine biodistribution. , 2013, ACS nano.

[14]  J. Bachmann,et al.  Targeted Near-Infrared Imaging of the Erythropoietin Receptor in Human Lung Cancer Xenografts , 2012, The Journal of Nuclear Medicine.

[15]  Yin Zhang,et al.  Positron Emission Tomography Imaging of CD105 Expression with a 64Cu-Labeled Monoclonal Antibody: NOTA Is Superior to DOTA , 2011, PloS one.

[16]  B. Pichler,et al.  [68Ga]NODAGA-RGD for imaging αvβ3 integrin expression , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  Guy Bormans,et al.  Optimal buffer choice of the radiosynthesis of 68Ga–Dotatoc for clinical application , 2010, Nuclear medicine communications.

[18]  K. Aoki,et al.  Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: Nonerythropoietin receptor-mediated pathways may play a major role. , 2009, Journal of pharmaceutical sciences.

[19]  M. Zwahlen,et al.  Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials , 2009, The Lancet.

[20]  H. Arai,et al.  Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. , 2008, Neoplasia.

[21]  D. Dorr,et al.  Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. , 2008, JAMA.

[22]  Wilson Roa,et al.  Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  H. Ogata,et al.  Pharmacokinetic study of darbepoetin alfa: Absorption, distribution, and excretion after a single intravenous and subcutaneous administration to rats , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[24]  M. Pepe,et al.  Do erythropoietin receptors on cancer cells explain unexpected clinical findings? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G. Schwarzer,et al.  Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. , 2006, Journal of the National Cancer Institute.

[26]  J. Spivak.  The anaemia of cancer: death by a thousand cuts , 2005, Nature Reviews Cancer.

[27]  Vasilis Ntziachristos,et al.  Looking and listening to light: the evolution of whole-body photonic imaging , 2005, Nature Biotechnology.

[28]  T. Chow,et al.  Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. , 2004, Molecular cancer therapeutics.

[29]  W. Jelkmann.  The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP , 2002, European journal of haematology.

[30]  T. Arakawa,et al.  The effect of carbohydrate on the structure and stability of erythropoietin. , 1991, The Journal of biological chemistry.

[31]  S. Masuda,et al.  The role of carbohydrate in recombinant human erythropoietin. , 1990, European journal of biochemistry.

[32]  S. Estrada,et al.  (68)Ga-Labeling of RGD peptides and biodistribution. , 2012, International journal of clinical and experimental medicine.

[33]  Kyung-Han Lee,et al.  In vivo characterization of 68Ga-NOTA-VEGF121 for the imaging of VEGF receptor expression in U87MG tumor xenograft models , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  G. Clemente,et al.  Synthesis and biological evaluation of 125 I-erythropoietin as a potential radiopharmaceutical agent for tumours , 2011 .

[35]  P. Falkai,et al.  Erythropoietin: a candidate compound for neuroprotection in schizophrenia , 2004, Molecular Psychiatry.